Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan

Virchows Archiv

Volumn 464, Issue 6, 2014, Pages 689-699

  Chen, Jim Ray ^a,b   Hsieh, Tsan Yu ^a,b   Chen, Huang Yang ^a,b   Yeh, Kun Yan ^a,b   Chen, Kuo Su ^a,b   ChangChien, Yi Che ^a,b   Pintye, Mariann ^a,b   Chang, Liang Che ^a,b   Hwang, Cheng Cheng ^a,b   Chien, Hui Ping ^a,b   Hsu, Yuan Chun ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Breast cancer; Chromogenic in situ hybridization; ESR1 amplification; Estrogen receptor; Fluorescent in situ hybridization; Tissue microarray

Indexed keywords

ESTROGEN RECEPTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; ESTROGEN RECEPTOR ALPHA GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEPTOR GENE; TAIWAN; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TAIWAN; TISSUE ARRAY ANALYSIS;

EID: 84902317098     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1576-8     Document Type: Article

References (37)

1. Tavassoli FA, Devilee P (2003)World health organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARCPress, Lyon
2. Manavathi B, Dey O, Gajulapalli VNR, Bhatia RS, Bugide S, Kumar R (2013) Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev 34:1-32. doi:10.1210/er.2011-1057
3. Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597-608
4. Bottner M, Thelen P, Jarry H (2013) Estrogen receptor beta: tissue distribution and the still largely enigmatic physiological function. J Steroid Biochem Mol Biol 20:52-56
5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
6. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323-1333. doi:10.1200/jco.2007.14.8197
7. Nembrot M, Quintana B, Mordoh J (1990) Estrogen receptor gene amplification is found in some estrogen receptor-positive human breast tumors. Biochem Biophys Res Commun 166:601-607 (Pubitemid 20049886)
8. Watts CK, Handel ML, King RJ, Sutherland RL (1992) Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol 41:529-536
9. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39:655-660 (Pubitemid 46676104)
10. Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:806-807 (Pubitemid 351913659)
11. Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, HanW, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Borresen-Dale AL, Pollack J, van de Vijver MJ (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:807-808 (Pubitemid 351913660)
12. Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809 (Pubitemid 351913661)
13. Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, Natrajan R, Salter J, Levey P, Fletcher O, Peto J, Ashworth A, Dowsett M (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809-810 (Pubitemid 351913662)
14. Adelaide J, Finetti P, Charafe-Jauffret E, Wicinski J, Jacquemier J, Sotiriou C, Bertucci F, Birnbaum D, Chaffanet M (2008) Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 123: 2970-2972
15. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Investig 88:491-503 (Pubitemid 351581454)
16. Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, Schmitt FC, Bussolati G, Ellis LO, Ashworth A, Sapino A, Reis-Filho JS (2008) Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215:398- 410
17. Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399-407
18. Moelans CB, Monsuur HN, de Pinth JH, Radersma RD, de Weger RA, van Diest PJ (2010) ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst) 33:13-18
19. Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura SS, Ikeda H, Kawashima H, Dobashi Y (2012) Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 227:8-16
20. Network TCGA(2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
21. Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT,Wang CC, Chang DY, Huang CS, Cheng AL (2013) Clinical significance of ESR1 gene copy number changes in breast cancer asmeasured by fluorescence in situ hybridisation. J Clin Pathol 66:140-145
22. Tomita S, Zhang Z, NakanoM, IbusukiM, Kawazoe T, Yamamoto Y, Iwase H (2009) Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100:1012-1017
23. Nielsen KV, Ejlertsen B,Muller S, Moller S, Rasmussen BB, Balslev E, Laenkholm AV, Christiansen P, Mouridsen HT (2011) Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 127:345-355
24. Burkhardt L, Grob TJ,Hermann I, Burandt E, ChoschzickM, Janicke F, Muller V, Bokemeyer C, Simon R, SauterG,WilczakW, Lebeau A (2010) Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 123:757-765
25. Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Muller S, Gelber RD, Price KN, Rasmussen BB, Viale G,Mouridsen H (2012) Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol 23:1138-1144
26. Gruver AM, Peerwani Z, Tubbs RR (2010) Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 63:210-219
27. Hwang CC, PintyeM, Chang LC, Chen HY, Yeh KY, Chien HP, Lee N, Chen JR (2011) Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology 59:984-992
28. Bartlett JM, Campbell FM, Ibrahim M, O'Grady A, Kay E, Faulkes C, Collins N, Starczynski J, Morgan JM, Jasani B,Miller K (2011) A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 135:157-162
29. Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL (2012) The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer 130:2629-2637
30. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual. Springer, Chicago
31. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481 (Pubitemid 29220854)
32. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368. doi:10.1634/ theoncologist.2008-0230
33. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12:1134-1142
34. Holst F, Stahl P, Hellwinkel O, Dancau A-M, Krohn A, Wuth L, Heupel C, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R (2008) Reply to "ESR1 gene amplification in breast cancer: a common phenomenon?". Nat Genet 40:810-812 (Pubitemid 351913663)
35. Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D'Addabbo P, Daniele G, L'Abbate A, Macchia G, Surace C, Kok K, Ullmann R, Purgato S, Palumbo O, Carella M, Ambros PF, Rocchi M (2010) Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res 20:1198-1206
36. Moelans CB, Holst F, Hellwinkel O, Simon R, van Diest PJ (2012) ESR1 gene amplification in breast cancer: influence of RNAse treatment on FISH results. [Abstr] Cancer Res 72(24 Suppl):P6-05-13
37. Gong Y, Sweet W, Duh YJ, Greenfield L, Fang Y, Zhao J, Tarco E, Symmans WF, Isola J, Sneige N (2009) Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol 131:490-497